329
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

The efficacy of abatacept focusing on anti-CCP antibody in Japanese patients with rheumatoid arthritis for 104 weeks

, , , , , , & show all
Pages 575-577 | Received 02 Nov 2016, Accepted 31 Jul 2017, Published online: 24 Aug 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Hisakata Yamada, Tomomi Tsuru, Takeshi Otsuka, Masayuki Maekawa, Hiroshi Harada, Takaaki Fukuda, Hiroshi Tsukamoto, Akira Maeyama, Shigeru Yoshizawa, Ken Wada, Yasuharu Nakashima, Eisuke Shono, Seiji Yoshizawa, Hiroshi Jojima & Masakazu Kondo. (2020) Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production. Immunological Medicine 43:2, pages 87-91.
Read now

Articles from other publishers (1)

Shuzo Yoshida, Takuya Kotani, Yuko Kimura, Yoko Matsumura, Ayaka Yoshikawa, Nao Tokai, Takuro Ozaki, Koji Nagai, Toru Takeuchi, Shigeki Makino & Shigeki Arawaka. (2019) Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single-center study. International Journal of Rheumatic Diseases 22:1, pages 81-89.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.